Obesity and Polycystic Ovary Syndrome
- PMID: 39701598
- PMCID: PMC11704221
- DOI: 10.7570/jomes24035
Obesity and Polycystic Ovary Syndrome
Abstract
The core pathophysiology of polycystic ovary syndrome involves an overproduction of androgens primarily originating from ovarian thecal cells. Two major external triggers promote androgen overproduction in the ovaries: the increased secretion of luteinizing hormone, a consequence of aberrant hypothalamic gonadotropin-releasing hormone secretion dynamics, and compensatory hyperinsulinemia resulting from insulin resistance. Obesity interacts with polycystic ovary syndrome in multiple ways, but a major role of obesity in its pathophysiology is the exacerbation of insulin resistance. Additionally, obesity contributes to polycystic ovary syndrome by facilitating the conversion of precursor hormones to testosterone within adipose cells. Moreover, obesity can lead to relative hyperandrogenemia, which is marked by lower levels of sex hormone binding globulin and increased availability of free testosterone to target tissues. Also, obesity affects the secretion of gonadotropins, resulting in heightened luteinizing hormone secretion or increased sensitivity of thecal cells to luteinizing hormone. Obesity-related insulin resistance might be amplified by alterations in adipokine and inflammatory cytokine production. Ultimately, obesity and polycystic ovary syndrome might share a common genetic predisposition. The cornerstone of managing polycystic ovary syndrome is to address individual symptoms such as hyperandrogenism (hirsutism, acne, and female type boldness), menstrual irregularities, and infertility stemming from anovulation. However, obesity is integral to the pathophysiology of polycystic ovary syndrome and exacerbates all of its features. Therefore, lifestyle modifications aimed at weight reduction should be the primary strategy in overweight or obese women with polycystic ovary syndrome.
Keywords: Anovulation; Insulin resistance; Obesity; Polycystic ovary syndrome.
Conflict of interest statement
The author declares no conflict of interest.
Figures

Similar articles
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC. Endocr Pract. 2015. PMID: 26509855
-
Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.Treat Endocrinol. 2006;5(3):171-87. doi: 10.2165/00024677-200605030-00005. Treat Endocrinol. 2006. PMID: 16677059
-
Obesity and the polycystic ovary syndrome.Int J Obes Relat Metab Disord. 2002 Jul;26(7):883-96. doi: 10.1038/sj.ijo.0801994. Int J Obes Relat Metab Disord. 2002. PMID: 12080440 Review.
-
Polycystic ovary syndrome.Endocrinol Metab Clin North Am. 1997 Dec;26(4):893-912. doi: 10.1016/s0889-8529(05)70286-3. Endocrinol Metab Clin North Am. 1997. PMID: 9429864 Review.
-
Polycystic Ovary Syndrome.Obstet Gynecol. 2018 Aug;132(2):321-336. doi: 10.1097/AOG.0000000000002698. Obstet Gynecol. 2018. PMID: 29995717 Review.
Cited by
-
The Anti-Mullerian Hormone as a Biomarker of Effectiveness of Metformin Hydrochloride Therapy in Polycystic Ovarian Syndrome and Insulin Resistance.Healthcare (Basel). 2025 Apr 11;13(8):884. doi: 10.3390/healthcare13080884. Healthcare (Basel). 2025. PMID: 40281834 Free PMC article. Review.
-
The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management.Pharmacy (Basel). 2025 Jul 11;13(4):95. doi: 10.3390/pharmacy13040095. Pharmacy (Basel). 2025. PMID: 40700266 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources